BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 32245629)

  • 1. Population-based genetic testing for Women's cancer prevention.
    Evans O; Gaba F; Manchanda R
    Best Pract Res Clin Obstet Gynaecol; 2020 May; 65():139-153. PubMed ID: 32245629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigating barriers to genetic counseling and germline mutation testing in women with suspected hereditary breast and ovarian cancer syndrome and Lynch syndrome.
    Shaw J; Bulsara C; Cohen PA; Gryta M; Nichols CB; Schofield L; O'Sullivan S; Pachter N; Hardcastle SJ
    Patient Educ Couns; 2018 May; 101(5):938-944. PubMed ID: 29273311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
    Graffeo R; Livraghi L; Pagani O; Goldhirsch A; Partridge AH; Garber JE
    Breast Cancer Res Treat; 2016 Dec; 160(3):393-410. PubMed ID: 27734215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA genetic testing of individuals from families with low prevalence of cancer: experiences of carriers and implications for population screening.
    Shkedi-Rafid S; Gabai-Kapara E; Grinshpun-Cohen J; Levy-Lahad E
    Genet Med; 2012 Jul; 14(7):688-94. PubMed ID: 22481128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of germline genetic mutations in patients with pancreatic cancer.
    Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
    Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial Results of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer and Lynch Syndrome.
    Howarth DR; Lum SS; Esquivel P; Garberoglio CA; Senthil M; Solomon NL
    Am Surg; 2015 Oct; 81(10):941-4. PubMed ID: 26463285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry.
    Manchanda R; Patel S; Antoniou AC; Levy-Lahad E; Turnbull C; Evans DG; Hopper JL; Macinnis RJ; Menon U; Jacobs I; Legood R
    Am J Obstet Gynecol; 2017 Nov; 217(5):578.e1-578.e12. PubMed ID: 28690137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome.
    Shulman LP
    Obstet Gynecol Clin North Am; 2010 Mar; 37(1):109-33, Table of Contents. PubMed ID: 20494261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests.
    Pujol P; Lyonnet DS; Frebourg T; Blin J; Picot MC; Lasset C; Dugast C; Berthet P; de Paillerets BB; Sobol H; Grandjouan S; Soubrier F; Buecher B; Guimbaud R; Lidereau R; Jonveaux P; Houdayer C; Giraud S; Olschwang S; Nogue E; Galibert V; Bara C; Nowak F; Khayat D; Nogues C
    Breast Cancer Res Treat; 2013 Aug; 141(1):135-44. PubMed ID: 23974829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review.
    Eccles DM; Balmaña J; Clune J; Ehlken B; Gohlke A; Hirst C; Potter D; Schroeder C; Tyczynski JE; Gomez Garcia EB
    Adv Ther; 2016 Feb; 33(2):129-50. PubMed ID: 26809252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hereditary breast/ovarian cancer--pitfalls in genetic counseling.
    Dagan E; Gershoni-Baruch R
    Clin Genet; 2001 Oct; 60(4):310-3. PubMed ID: 11683778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A clinical guide to hereditary cancer panel testing: evaluation of gene-specific cancer associations and sensitivity of genetic testing criteria in a cohort of 165,000 high-risk patients.
    LaDuca H; Polley EC; Yussuf A; Hoang L; Gutierrez S; Hart SN; Yadav S; Hu C; Na J; Goldgar DE; Fulk K; Smith LP; Horton C; Profato J; Pesaran T; Gau CL; Pronold M; Davis BT; Chao EC; Couch FJ; Dolinsky JS
    Genet Med; 2020 Feb; 22(2):407-415. PubMed ID: 31406321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cancer genetics: estimation of the needs of the population in France for the next ten years].
    Bonaïti-Pellié C; Andrieu N; Arveux P; Bonadona V; Buecher B; Delpech M; Jolly D; Julian-Reynier C; Luporsi E; Noguès C; Nowak F; Olschwang S; Orsi F; Pujol P; Saurin JC; Sinilnikova O; Stoppa-Lyonnet D; Thépot F
    Bull Cancer; 2009 Sep; 96(9):875-900. PubMed ID: 19751997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical and molecular diagnosis of inherited breast-ovarian cancer].
    Chompret A
    J Gynecol Obstet Biol Reprod (Paris); 2003 Apr; 32(2):101-19. PubMed ID: 12717301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients.
    Vergote I; Banerjee S; Gerdes AM; van Asperen C; Marth C; Vaz F; Ray-Coquard I; Stoppa-Lyonnet D; Gonzalez-Martin A; Sehouli J; Colombo N
    Eur J Cancer; 2016 Dec; 69():127-134. PubMed ID: 27821315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hereditary cancer-associated mutations in women diagnosed with two primary cancers: an opportunity to identify hereditary cancer syndromes after the first cancer diagnosis.
    Saam J; Moyes K; Landon M; Williams K; Kaldate RR; Arnell C; Wenstrup R
    Oncology; 2015; 88(4):226-33. PubMed ID: 25503195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force.
    Nelson HD; Huffman LH; Fu R; Harris EL;
    Ann Intern Med; 2005 Sep; 143(5):362-79. PubMed ID: 16144895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attitude towards and factors affecting uptake of population-based BRCA testing in the Ashkenazi Jewish population: a cohort study.
    Manchanda R; Burnell M; Gaba F; Sanderson S; Loggenberg K; Gessler S; Wardle J; Side L; Desai R; Brady AF; Dorkins H; Wallis Y; Chapman C; Jacobs C; Tomlinson I; Beller U; Menon U; Jacobs I
    BJOG; 2019 May; 126(6):784-794. PubMed ID: 30767407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice.
    Menko FH; Ter Stege JA; van der Kolk LE; Jeanson KN; Schats W; Moha DA; Bleiker EMA
    Fam Cancer; 2019 Jan; 18(1):127-135. PubMed ID: 29846880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development.
    Koren-Michowitz M; Friedman E; Gershoni-Baruch R; Brok-Simoni F; Patael Y; Rechavi G; Amariglio N
    Am J Hematol; 2005 Mar; 78(3):203-6. PubMed ID: 15726604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.